rHuEPO
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT00491868 | Jun 2007 → May 2008 | — | Chugai Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT02767765 | Jun 2003 → Oct 2006 | anemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 2 | NCT04231292 Comparator | Mar → Jun 2020 | anemia | Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT03950687 Comparator | Jun 2019 → Jun 2020 | chronic renal failure syndrome | Shenyang Sunshine Pharmaceutical Co., LTD. | Unknown | No outcome recorded |
| Phase 2 | NCT00744445 Comparator | Oct 1993 → Aug 1998 | anemia, chronic renal failure syndrome | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 3 | NCT06720025 Comparator | Sep 2023 → Jun 2024 | anemia | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00111137 Comparator | Feb → Nov 2003 | cancer | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00038064 Comparator | Jan 2002 → Oct 2003 | anemia, neoplasm | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00527137 Comparator | Aug 2000 → Nov 2004 | end stage renal failure | Amgen | Completed | Met primary |
| Phase 4 | NCT07045155 Comparator | Aug 2025 → Dec 2027 expected | anemia due to chronic disorder, end stage renal failure | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04655027 Comparator | Feb → Oct 2021 | anemia due to chronic disorder | AstraZeneca | Completed | Missed primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2010-12-04 | Ligand Pharmaceuticals | Ligand Announces Positive Preclinical Data on Small Molecule Erythropoietin Receptor Agonists ligand.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rHuEpo | “Pilot Study for Evaluating the Efficacy and Tolerability of Induction Therapy With Recombinant Human Erythropoietin Beta (rHuEPO) NeoRecormon® - at High Dose in Anemic Cancer...” NCT02767765 ↗12“comparing the efficacy of darbepoetin alfa with that of recombinant human erythropoietin (rHuEpo) in pediatric subjects with CKD.” PMID 16724235 ↗ May 2006 “rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin” NCT04231292 ↗ “rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin” NCT03950687 ↗ “Drug: rHuEPO” NCT00491868 ↗ |
| Known as | erythropoietin | “The purpose of this research study was to determine if the activity of erythropoietin (r-HuEPO) is time dependent when given to chronic renal failure patients at three...” NCT00744445 ↗ |
| Known as | Recombinant Human Erythropoietin | “compare the time to hematopoietic response (hemoglobin correction to 12 g/dL or a greater than or equal to 2 g/dL increase from baseline) for subjects randomized to receive...” NCT00111137 ↗2“roxadustat versus recombinant human erythropoietin (rHuEPO) on gastrointestinal iron absorption in patients with anemia of CKD (stage 4/5).” PMID 38280066 ↗ Jan 2024 “who have been receiving recombinant human erythropoietin (rHuEPO) treatment for at least 4 weeks” NCT07045155 ↗ |
| Known as | Recombinant Human Erythropoietin Beta | “Pilot Study for Evaluating the Efficacy and Tolerability of Induction Therapy With Recombinant Human Erythropoietin Beta (rHuEPO) NeoRecormon® - at High Dose in Anemic Cancer...” NCT02767765 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human erythropoietin has been produced in the laboratory and has the same effect as the hormone produced by the body.” NCT00038064 ↗ |
| Route | Intravenous | “2250IU or 3000IU(i.v.)” NCT00491868 ↗ |